MGC Pharma (ASX:MXC) tackles COVID afterburner

Post-COVID inflammation is not only highly uncomfortable but has been linked with post-recovery mortality.

COVID-related inflammation, along with other symptoms, last weeks and can often last months.

Some liken it to another form of chronic fatigue.

Those with existing medical conditions who contract COVID-19 tend to have a much harder road to recovery, or COVID could worsen their condition, depending on the condition.

Additionally, the relatively misunderstood effects of long COVID are increasingly coming to the fore, with persistent inflammation thought to be connected to a specific type of immune cell called macrophages showing altered inflammatory and metabolic expression several months after mild COVID-19.

And until now, suggestive steroid treatments, which carry their potential health consequences, have been the mainstay of limited treatment choices associated with decreased post-acute COVID-19 mortality risk.

Cannabinoid molecular structure

European-based MGC Pharmaceuticals has released encouraging preclinical and clinical rodent studies demonstrating the effectiveness of its naturally occurring phytocannabinoid-based CimetraA for the prevention of severe inflammation.

“Based on the mechanism of action of CimetrA, we suppose that it should prevent the symptoms of Long Covid,” MGC Chief Medical Officer Nadya Lisovoder said.

“In the current clinical study, we focus on this question (among others).

About the Trial

Preclinical and clinical results to date have demonstrated CimetrATM’s mechanism of action as an anti-inflammatory and immunomodulatory agent, which is effective in the prevention of severe inflammation by its control of increased Cytokine production resulting from an infection of the different variants of SARS-CoV-2 (the virus responsible for COVID-19); and which is the forerunner of a Cytokine Storm, which is believed to be the main reason for mortality in severe COVID-19 patients.

Next Steps

An interim analysis in February is expected to provide preliminary data the Company is confident will support its claim.

“The results of the preclinical studies we performed during the R&D process, including the last published results, support the assumption regarding the effect of CimetrA on Long Covid,” Dr Lisovoder said.

Price Action

The Company’s ASX-listed price is 1.1c in early afternoon trade.

About CimetrATM

CimetrATM is a nanoparticle micellar formulation based on the pharmaceutical synergetic composition Curcumin and Boswellia. In preclinical and clinical trials, C, imetrATM has demonstrated anti-inflammatory immunomodulating effects.

Fundamental Data

Please note the following valuable information before using this website. 

Independent Research 

Market Open Australia is intended to be used only for educational and informative purposes, and any information on this website should not be taken as investment advice or guidance. It is important to conduct your own research before making any investment decisions, which should be based on your own investment needs and personal circumstances. Any investment decisions based on information contained on this website should be taken in line with independent financial advice from a qualified professional or should be independently researched and verified.